Tag archive

Pharmacosmos

Iron isomaltoside and ferric carboxymaltose on hypophosphatemic effects in a controlled trial

in Pharmaceutical News
Press release: New study demonstrates significant difference between iron isomaltoside and ferric carboxymaltose on hypophosphatemic effects in a controlled, randomized clinical investigation

Results of a study comparing the incidence of hypophosphatemia after high dose IV iron substitution have been presented at the 60th annual meeting of the American Society of Hematology. The HOMe aFers trial recruited women with gynaecological bleeding and subsequent iron deficiency. All subjects were given high dose intravenous iron, randomised between iron isomaltoside and ferric carboxymaltose to correct their iron deficiency. It has been reported[1] that ferric carboxymaltose has a propensity to induce hypophosphatemia. This independent study was conducted…

Keep Reading

Pharmacosmos introduces DEAE-Dextran

in Pharmaceutical News

[wp_ad_camp_4]Dextran-supplier Pharmacosmos extends its quality dextran offerings with DEAE-Dextran, manufactured in the company’s FDA and EDQM-approved facility in Denmark. Holbæk, Denmark, July 14, 2015 – Pharmacosmos introduces DEAE-Dextran as part of the company’s extensive array of biopolymers for pharmaceutical use. The company sees the introduction as part of a dedicated continuing effort to developing and supplying its customers’ clinical grade dextran derivatives. ”Our DEAE-Dextran is graced with the same high quality as our other dextran products, and we believe that…

Keep Reading

Go to Top